INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 459m ago
HOUSE PTR59m ago
SEC 13F59m ago
ROBINHOOD CHAIN59m ago
Public company

KPTIKaryopharm Therapeutics Inc.

CIK 0001503802

EDGAR filingsOpen in network
Disclosed transactions2
Buys / sells0 / 1
Max Insider Score21
Connections4with evidence

KPTI · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
15
SZ
Su ZhenDirector
KPTIKaryopharm Therapeutics Inc.
Grant or award
A—
15.5K sh
May 21, 2026May 26, 2026
traded May 21, 2026
+5dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    SIDLEY AUSTIN LLPLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Su ZhenDirector · May 26, 2026
  • ← Insider ofevidence
    Rangwala ReshmaEVP & Chief Medical Officer · Apr 22, 2026
21
RR
Rangwala ReshmaEVP & Chief Medical Officer
KPTIKaryopharm Therapeutics Inc.
Open-market sale
SELL
$4,014
449 sh
Apr 21, 2026
Apr 22, 2026
traded Apr 21, 2026
+1d
SEC FORM 4

Evidence

Lobbying

$0 reported · de-duplicated
2026 Q2 $0 via firms2026 Q1 $0 via firms
  • SIDLEY AUSTIN LLP—2026 Q1 · posted Aug 26, 2026 · Health issues
  • SIDLEY AUSTIN LLP—2026 Q2 · posted Aug 26, 2026 · Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.